Recombinant DNA technology is the original method of genetic engineering and the foundation upon which modern synthetic biology is built. Developed in the early 1970s by Stanley Cohen and Herbert Boyer, the technique uses restriction enzymes to cut DNA at specific sequences and DNA ligase to join fragments from different organisms together. This allows a gene from one species to be inserted into another, creating organisms with new capabilities — such as bacteria that produce human insulin or crops resistant to herbicides.
The impact of recombinant DNA technology on medicine and industry has been transformative. The first recombinant DNA pharmaceutical, human insulin produced by engineered E. coli (Humulin by Genentech/Eli Lilly), was approved in 1982. Since then, hundreds of recombinant proteins have reached the market, including growth hormones, clotting factors, monoclonal antibodies, and vaccines. The entire biopharmaceutical industry — now worth hundreds of billions of dollars annually — is built on recombinant DNA foundations.
While newer tools like CRISPR and whole-gene synthesis have expanded the genetic engineering toolkit enormously, recombinant DNA methods remain in routine daily use in laboratories and manufacturing facilities worldwide. The principles of cutting, pasting, and recombining genetic sequences are still fundamental to constructing the engineered organisms used in synthetic biology. Understanding recombinant DNA technology provides essential context for appreciating the more advanced capabilities that CRISPR, gene circuits, and genome-scale engineering represent. For deeper coverage, see SynBioIntel.